Hossein Borghaei

Professor and Chief, Thoracic Oncology

Fox Chase Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hossein Borghaei is a Professor and Chief of Thoracic Oncology at Fox Chase Cancer Center in the United States. His research primarily focuses on small cell lung cancer and immunotherapy, as evidenced by his recent publications on patient-reported outcomes and management of adverse events related to tarlatamab. He also investigates treatment patterns and survival rates among lung cancer patients, along with the role of genetic mutations in therapy response. Dr. Borghaei's work aims to address unmet needs and improve outcomes in lung cancer management and research.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Brian Egleston

Research Professor

Fox Chase Cancer Center

UNITED STATES

View details

Apar Kishor Ganti

Professor

University of Nebraska Medical Center

UNITED STATES

View details

Fiona Blackhall

The University of Manchester

UNITED KINGDOM

View details

Delvys Rodriguez-Abreu

Universidad de Las Palmas de Gran Canaria

SPAIN

View details

Rosalyn Juergens

CANADA

View details

Keith Eaton

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Erica Golemis

Program Leader; Professor; Deputy Chief Science Officer

Fox Chase Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hossein Borghaei

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial

Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer

Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Calls to action on lung cancer management and research

Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol

Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers

Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer

Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Collaborators (7)

Brian Egleston

Apar Kishor Ganti

Fiona Blackhall

Delvys Rodriguez-Abreu

Rosalyn Juergens

Keith Eaton

Erica Golemis

Make your next move.